1 |
CHEN D, ZHAO Y J, LI M Y, et al. A general Fc engineering platform for the next generation of antibody therapeutics[J]. Theranostics, 2021, 11(4): 1901-1917.
|
2 |
KAPLON H, MURALIDHARAN M, SCHNEIDER Z, et al. Antibodies to watch in 2020[J]. mAbs, 2020, 12(1): 1703531.
|
3 |
MULLARD A. FDA approves 100th monoclonal antibody product[J]. Nat Rev Drug Discov, 2021, 20(7): 491-495.
|
4 |
SHIELDS R L, NAMENUK A K, HONG K, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR[J]. J Biol Chem, 2001, 276(9): 6591-6604.
|
5 |
RICHARDS J O, KARKI S, LAZAR G A, et al. Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells[J]. Mol Cancer Ther, 2008, 7(8): 2517-2527.
|
6 |
SONDERMANN P, KAISER J, JACOB U. Molecular basis for immune complex recognition: a comparison of Fc-receptor structures[J]. J Mol Biol, 2001, 309(3): 737-749.
|
7 |
LIU R N, OLDHAM R J, TEAL E, et al. Fc-engineering for modulated effector functions-improving antibodies for cancer treatment[J]. Antibodies (Basel), 2020, 9(4): 64.
|
8 |
NORDSTROM J L, GORLATOV S, ZHANG W J, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties[J]. Breast Cancer Res, 2011, 13(6): R123.
|
9 |
MASON D M, WEBER C R, PAROLA C, et al. High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesis[J]. Nucleic Acids Res, 2018, 46(14): 7436-7449.
|
10 |
WERNERSSON R. Virtual ribosome: a comprehensive DNA translation tool with support for integration of sequence feature annotation[J]. Nucleic Acids Res, 2006, 34(web server issue): W385-W388.
|
11 |
LAZAR G A, DANG W, KARKI S, et al. Engineered antibody Fc variants with enhanced effector function[J]. Proc Natl Acad Sci USA, 2006, 103(11): 4005-4010.
|
12 |
MIMOTO F, KATADA H, KADONO S, et al. Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa (R131) and FcγRIIa (H131)[J]. Protein Eng Des Sel, 2013, 26(10): 589-598.
|
13 |
SMITH G P. Phage display: simple evolution in a petri dish (Nobel lecture)[J]. Angew Chem Int Ed Engl, 2019, 58(41): 14428-14437.
|
14 |
LERNER R A. Manufacturing immunity to disease in a test tube: the magic bullet realized[J]. Angew Chem Int Ed Engl, 2006, 45(48): 8106-8125.
|
15 |
NADEEM T, KHAN M A, IJAZ B, et al. Glycosylation of recombinant anticancer therapeutics in different expression systems with emerging technologies[J]. Cancer Res, 2018, 78(11): 2787-2798.
|
16 |
BEERLI R R, BAUER M, BUSER R B, et al. Isolation of human monoclonal antibodies by mammalian cell display[J]. Proc Natl Acad Sci USA, 2008, 105(38): 14336-14341.
|
17 |
ZHANG J, ZHANG X A, LIU Q, et al. Mammalian cell display for rapid screening scFv antibody therapy[J]. Acta Biochim Biophys Sin (Shanghai), 2014, 46(10): 859-866.
|
18 |
BRUUN T H, GRASSMANN V, ZIMMER B, et al. Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins[J]. mAbs, 2017, 9(7): 1052-1064.
|